Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook

Rahul Shrimanker; Ian D Pavord

doi:10.1007/s40259-017-0215-8

Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook

BioDrugs. 2017 Apr;31(2):93-103. doi: 10.1007/s40259-017-0215-8.

Authors

Rahul Shrimanker¹, Ian D Pavord²

Affiliations

¹ Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Oxford, OX3 7FZ, UK.
² Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Oxford, OX3 7FZ, UK. Ian.pavord@ndm.ox.ac.uk.

PMID: 28364396
DOI: 10.1007/s40259-017-0215-8

Abstract

In this review, we outline the pathophysiology of severe asthma and discuss the role of anti-interleukin (IL)-5 inhibitors for the treatment of asthma. Anti-IL-5 treatments have shown efficacy in reducing the rate of severe asthma attacks in eosinophilic asthma. We review the history of the development of these agents, lessons learnt about severe asthma along the way and key clinical trials supporting efficacy of the three anti-IL-5 treatments that are clinically available or undergoing clinical trials in asthma.

Publication types

Review

MeSH terms

Anti-Asthmatic Agents / pharmacology*
Antibodies, Monoclonal, Humanized / pharmacology
Asthma / drug therapy*
Asthma / physiopathology
Eosinophils / drug effects
Eosinophils / pathology
Humans
Interleukin-5 / antagonists & inhibitors*
Molecular Targeted Therapy / methods
Receptors, Interleukin-5 / antagonists & inhibitors

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
IL5 protein, human
Interleukin-5
Receptors, Interleukin-5
reslizumab
benralizumab
mepolizumab